top of page
Dynamic Drug Advancement Limited | Durham Institute of Respirology
About the Trial
The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will evaluate the incidence of asthma exacerbations, other pharmacodynamic (PD) parameters such as lung function and asthma control, and the safety and tolerability of verekitug (UPB-101) compared to placebo.
Mechanism of Action:
Duration of Study
~80 weeks
Phase
2
Principal Investigator
Dr. George Philteos
Sub-Investigator
Dr. Anushya Chelvanathan
Study Coordinator
Nusrat Jahan
bottom of page